Which angiotensin receptor blocker (ARB) is appropriate for a patient with an ejection fraction of 20%?

Which ARB for EF 20%?

For a patient with an ejection fraction of 20%, use candesartan, valsartan, or losartan—these are the three ARBs with proven mortality and morbidity benefits in heart failure with reduced ejection fraction. 1, 2, 3

Specific ARB Recommendations

The evidence-based ARBs for severe systolic dysfunction (EF 20%) are:

• Candesartan: Start 4-8 mg daily, target 32 mg daily 1, 2, 3
• Valsartan: Start 40 mg twice daily, target 160 mg twice daily 1, 2, 3
• Losartan: Start 25-50 mg daily, target 150 mg daily 1, 3

These three agents have demonstrated reduction in hospitalizations and mortality in landmark trials of HFrEF patients 2, 3.

Critical Context: ARBs Are Second-Line

ARBs should only be used if ACE inhibitors are not tolerated (due to cough or angioedema) or if an ARNI (sacubitril/valsartan) is not feasible 4, 5. With an EF of 20%, this patient has severe systolic dysfunction and should ideally receive:

1. First choice: ARNI (sacubitril/valsartan 24/26-49/51 mg twice daily, target 97/103 mg twice daily) 4, 5
2. Second choice: ACE inhibitor if ARNI not feasible 4, 5
3. Third choice: ARB only if ACE inhibitor intolerant 4, 5

Practical Initiation Strategy

When starting an ARB in severe HFrEF (EF 20%):

• Check baseline: Creatinine, potassium, blood pressure
• Start low: Use the lower starting doses listed above
• Monitor closely: Recheck labs in 1-2 weeks after initiation
• Acceptable changes: Creatinine increase up to 50% above baseline (or up to 266 μmol/L/3 mg/dL), potassium up to 5.5 mmol/L 6
• Titrate gradually: Double dose every 2-4 weeks as tolerated toward target doses
• Stop if: Potassium >5.5 mmol/L, creatinine increases >100% or >310 μmol/L (3.5 mg/dL) 6

Complete GDMT Framework

An EF of 20% mandates quadruple therapy ("four pillars") 4, 5:

1. Renin-angiotensin system inhibition (ARNI > ACEi > ARB)
2. Beta-blocker (bisoprolol, carvedilol, or metoprolol succinate) 4, 5
3. Mineralocorticoid receptor antagonist (spironolactone or eplerenone) if K+ <5.0 and eGFR >30 4, 5
4. SGLT2 inhibitor (dapagliflozin 10 mg or empagliflozin 10 mg daily) 1, 4, 5

All four should be initiated rapidly—ideally within 4 weeks—as benefits emerge quickly, particularly with SGLT2 inhibitors 7, 8.

Common Pitfalls

• Don't use ARBs as first-line: ACE inhibitors remain first choice when ARNI not feasible 4, 5
• Don't combine ARB + ACEi routinely: Triple renin-angiotensin blockade (ARB + ACEi + MRA) increases hyperkalemia and renal dysfunction risk without clear benefit 2, 3
• Don't delay other pillars: Start beta-blocker, MRA, and SGLT2i concurrently—don't wait for ARB titration 4, 5, 8
• Angioedema caution: While rare, angioedema can occur with ARBs in patients who had it with ACE inhibitors—use extreme caution 2, 3